{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:17:40Z","timestamp":1787872660122,"version":"build-2784847793"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key Research Program of Guangxi Science and Technology Department","award":["AB21196010"],"award-info":[{"award-number":["AB21196010"]}]},{"name":"Self-funded Scientific Research Project of the Health Commission of Guangxi Zhuang Autonomous Region","award":["No.Z-A20240492, Z-A20240515"],"award-info":[{"award-number":["No.Z-A20240492, Z-A20240515"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82104499, 82160783"],"award-info":[{"award-number":["82104499, 82160783"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Joint Project on Regional High-Incidence Diseases Research of Guangxi Natural Science Foundation","award":["No.2023GXNSFBA026146"],"award-info":[{"award-number":["No.2023GXNSFBA026146"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2023MD734158"],"award-info":[{"award-number":["2023MD734158"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-026-04340-w","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:59:49Z","timestamp":1781780389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global landscape for pulmonary fibrosis treatment: a data-driven perspective from clinical trials"],"prefix":"10.1186","volume":"26","author":[{"given":"Chunyan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaochu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhai","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"12","key":"4340_CR1","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.molmed.2023.08.010","volume":"29","author":"T Koudstaal","year":"2023","unstructured":"Koudstaal T, Funke-Chambour M, Kreuter M, Molyneaux PL, Wijsenbeek MS. Pulmonary fibrosis: from pathogenesis to clinical decision-making. Trends Mol Med. 2023;29(12):1076\u201387.","journal-title":"Trends Mol Med"},{"issue":"2","key":"4340_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/crj.13466","volume":"16","author":"DS Glass","year":"2022","unstructured":"Glass DS, Grossfeld D, Renna HA, Agarwala P, Spiegler P, DeLeon J, et al. Idiopathic pulmonary fibrosis: Current and future treatment. Clin Respir J. 2022;16(2):84\u201396.","journal-title":"Clin Respir J"},{"key":"4340_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev-pathol-042320-030240","volume":"17","author":"BJ Moss","year":"2022","unstructured":"Moss BJ, Ryter SW, Rosas IO. Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis. Annu Rev Pathol. 2022;17:515\u201346.","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"4340_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.33549\/physiolres.935322","volume":"73","author":"J Muri","year":"2024","unstructured":"Muri J, Durcov\u00e1 B, Slivka R, Vrbensk\u00e1 A, Makovick\u00e1 M, Makovick\u00fd P, et al. Idiopathic Pulmonary Fibrosis: Review of Current Knowledge. Physiol Res. 2024;73(4):487\u201397.","journal-title":"Physiol Res"},{"issue":"1","key":"4340_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1186\/s12967-021-03159-9","volume":"19","author":"WJ Huang","year":"2021","unstructured":"Huang WJ, Tang XX. Virus infection induced pulmonary fibrosis. J Transl Med. 2021;19(1):496.","journal-title":"J Transl Med"},{"issue":"7","key":"4340_CR6","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.immuni.2025.05.007","volume":"58","author":"D Qiu","year":"2025","unstructured":"Qiu D, Zhang S, Huang C, Wang X, Deng J, Sun H, et al. Dectin-1 facilitates lung fungal-mediated pulmonary fibrosis. Immunity. 2025;58(7):1811\u2013e298.","journal-title":"Immunity"},{"key":"4340_CR7","doi-asserted-by":"crossref","unstructured":"Mukherjee M, Kolb M. A novel take on idiopathic pulmonary fibrosis disease progression: localised autoimmunity. Eur Respir J. 2023;61(5):2300653.","DOI":"10.1183\/13993003.00653-2023"},{"issue":"6","key":"4340_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/17476348.2021.1916472","volume":"15","author":"SE Tanni","year":"2021","unstructured":"Tanni SE, Fabro AT, de Albuquerque A, Ferreira EVM, Verrastro CGY, Sawamura MVY, et al. Pulmonary fibrosis secondary to COVID-19: a narrative review. Expert Rev Respir Med. 2021;15(6):791\u2013803.","journal-title":"Expert Rev Respir Med"},{"key":"4340_CR9","doi-asserted-by":"publisher","first-page":"116357","DOI":"10.1016\/j.ecoenv.2024.116357","volume":"277","author":"J Zhang","year":"2024","unstructured":"Zhang J, Du J, Liu D, Zhuo J, Chu L, Li Y, et al. Polystyrene microplastics induce pulmonary fibrosis by promoting alveolar epithelial cell ferroptosis through cGAS\/STING signaling. Ecotoxicol Environ Saf. 2024;277:116357.","journal-title":"Ecotoxicol Environ Saf"},{"issue":"2","key":"4340_CR10","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192(2):e3\u201319.","journal-title":"Am J Respir Crit Care Med"},{"issue":"22","key":"4340_CR11","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr., Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med"},{"issue":"22","key":"4340_CR12","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"1","key":"4340_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40\u201351.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"4340_CR14","doi-asserted-by":"publisher","first-page":"e12385","DOI":"10.1002\/trc2.12385","volume":"9","author":"J Cummings","year":"2023","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer\u2019s disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023;9(2):e12385.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"26","key":"4340_CR15","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019;380(26):2518\u201328.","journal-title":"N Engl J Med"},{"key":"4340_CR16","doi-asserted-by":"crossref","unstructured":"Bermudo-Peloche G, Del Rio B, Vicens-Zygmunt V, Bordas-Martinez J, Hern\u00e1ndez M, Valenzuela C et al. Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial: Eur Respir J. 2025;65(4):2402249","DOI":"10.1183\/13993003.02249-2024"},{"issue":"4","key":"4340_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2008470","volume":"384","author":"A Waxman","year":"2021","unstructured":"Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, et al. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med. 2021;384(4):325\u201334.","journal-title":"N Engl J Med"},{"issue":"4","key":"4340_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000342027","volume":"85","author":"J Br\u00e4unlich","year":"2013","unstructured":"Br\u00e4unlich J, Beyer D, Mai D, Hammerschmidt S, Seyfarth HJ, Wirtz H. Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients. Respiration. 2013;85(4):319\u201325.","journal-title":"Respiration"},{"issue":"6","key":"4340_CR19","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1183\/09031936.00104612","volume":"42","author":"G Raghu","year":"2013","unstructured":"Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J. 2013;42(6):1622\u201332.","journal-title":"Eur Respir J"},{"issue":"4","key":"4340_CR20","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.chest.2022.11.035","volume":"163","author":"SM Matson","year":"2023","unstructured":"Matson SM, Baqir M, Moua T, Marll M, Kent J, Iannazzo NS, et al. Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory. Chest. 2023;163(4):861\u20139.","journal-title":"Chest"},{"issue":"1","key":"4340_CR21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1186\/s13063-022-06720-z","volume":"23","author":"J Ekl\u00f6f","year":"2022","unstructured":"Ekl\u00f6f J, Alispahic IA, Sivapalan P, Wilcke T, Seersholm N, Armbruster K, et al. Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma? A multicenter, randomized, controlled, open-label trial. Trials. 2022;23(1):817.","journal-title":"Trials"},{"issue":"12","key":"4340_CR22","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1513\/AnnalsATS.202103-266OC","volume":"18","author":"SA Guler","year":"2021","unstructured":"Guler SA, Clarenbach C, Brutsche M, Hostettler K, Brill AK, Schertel A, et al. Azithromycin for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis: A Randomized Controlled Crossover Trial. Ann Am Thorac Soc. 2021;18(12):2018\u201326.","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"4340_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12890-021-01783-1","volume":"21","author":"JP Finnerty","year":"2021","unstructured":"Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm Med. 2021;21(1):411.","journal-title":"BMC Pulm Med"},{"key":"4340_CR24","first-page":"101676","volume":"38","author":"EV Filimonova","year":"2022","unstructured":"Filimonova EV, Davydova LA, Lysenko MA, Tsarenko SV. Interstitial inflammation and pulmonary fibrosis in COVID-19: The potential role of cytostatic therapy for severe lung injury. Respiratory Med case Rep. 2022;38:101676.","journal-title":"Respiratory Med case Rep"},{"issue":"8","key":"4340_CR25","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S2213-2600(20)30225-3","volume":"8","author":"PM George","year":"2020","unstructured":"George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respiratory Med. 2020;8(8):807\u201315.","journal-title":"Lancet Respiratory Med"},{"issue":"18","key":"4340_CR26","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"8","key":"4340_CR27","doi-asserted-by":"publisher","first-page":"e0134826","DOI":"10.1371\/journal.pone.0134826","volume":"10","author":"C Tenopir","year":"2015","unstructured":"Tenopir C, Dalton ED, Allard S, Frame M, Pjesivac I, Birch B, et al. Changes in Data Sharing and Data Reuse Practices and Perceptions among Scientists Worldwide. PLoS ONE. 2015;10(8):e0134826.","journal-title":"PLoS ONE"},{"issue":"5","key":"4340_CR28","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/MCP.0000000000001099","volume":"30","author":"P Spagnolo","year":"2024","unstructured":"Spagnolo P, Maher TM. The future of clinical trials in idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2024;30(5):494\u20139.","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"4340_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12880-022-00803-8","volume":"22","author":"WJ Wu","year":"2022","unstructured":"Wu WJ, Huang WM, Liang CH, Yun CH. Pulmonary vascular volume is associated with DLCO and fibrotic score in idiopathic pulmonary fibrosis: an observational study. BMC Med Imaging. 2022;22(1):76.","journal-title":"BMC Med Imaging"},{"key":"4340_CR30","doi-asserted-by":"crossref","unstructured":"Clynick B, Corte TJ, Jo HE, Stewart I, Glaspole IN, Grainge C et al. Biomarker signatures for progressive idiopathic pulmonary fibrosis: Eur Respir J. 2022;59(3):2101181.","DOI":"10.1183\/13993003.01181-2021"},{"key":"4340_CR31","doi-asserted-by":"crossref","unstructured":"Sica G, D\u2019Agnano V, Bate ST, Romano F, Viglione V, Franzese L et al. Integrating Radiomics Signature into Clinical Pathway for Patients with Progressive Pulmonary Fibrosis. Diagnostics (Basel Switzerland). 2025;15(3):278.","DOI":"10.3390\/diagnostics15030278"},{"key":"4340_CR32","doi-asserted-by":"crossref","unstructured":"Stefano A, Gio\u00e8 M, Russo G, Palmucci S, Torrisi SE, Bignardi S et al. Performance of Radiomics Features in the Quantification of Idiopathic Pulmonary Fibrosis from HRCT. Diagnostics (Basel Switzerland). 2020;10(5):306.","DOI":"10.3390\/diagnostics10050306"},{"issue":"5","key":"4340_CR33","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jama.2024.8693","volume":"332","author":"G Raghu","year":"2024","unstructured":"Raghu G, Richeldi L, Fern\u00e1ndez P\u00e9rez ER, De Salvo MC, Silva RS, Song JW, et al. Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial. JAMA. 2024;332(5):380\u20139.","journal-title":"JAMA"},{"issue":"2","key":"4340_CR34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1164\/rccm.202405-0977OC","volume":"211","author":"TJ Corte","year":"2025","unstructured":"Corte TJ, Behr J, Cottin V, Glassberg MK, Kreuter M, Martinez FJ, et al. Efficacy and Safety of Admilparant, an LPA(1) Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. Am J Respir Crit Care Med. 2025;211(2):230\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"4340_CR35","doi-asserted-by":"crossref","unstructured":"Corte TJ, Lancaster L, Swigris JJ, Maher TM, Goldin JG, Palmer SM et al. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ open respiratory Res. 2021;8(1):e001026.","DOI":"10.1136\/bmjresp-2021-001026"},{"issue":"9","key":"4340_CR36","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1164\/rccm.202112-2824OC","volume":"206","author":"G Raghu","year":"2022","unstructured":"Raghu G, Mouded M, Chambers DC, Martinez FJ, Richeldi L, Lancaster LH, et al. A Phase IIb Randomized Clinical Study of an Anti-\u03b1(v)\u03b2(6) Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022;206(9):1128\u201339.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"4340_CR37","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1164\/rccm.202208-1579ED","volume":"206","author":"P Sime","year":"2022","unstructured":"Sime P, Jenkins G. Goldilocks and the Three Trials: Clinical Trials Targeting the \u03b1(v)\u03b2(6) Integrin in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022;206(9):1062\u20133.","journal-title":"Am J Respir Crit Care Med"},{"issue":"22","key":"4340_CR38","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","volume":"392","author":"L Richeldi","year":"2025","unstructured":"Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025;392(22):2193\u2013202.","journal-title":"N Engl J Med"},{"issue":"4","key":"4340_CR39","doi-asserted-by":"publisher","first-page":"102404","DOI":"10.1016\/j.cpcardiol.2024.102404","volume":"49","author":"G Cueto-Robledo","year":"2024","unstructured":"Cueto-Robledo G, Tovar-Benitez D, Alfaro-Cruz A, Gonzalez-Hermosillo LM. Systemic scleroderma: Review and updated approach and case description to addressing pulmonary arterial hypertension and idiopathic pulmonary fibrosis: A dual challenge in treatment. Curr Probl Cardiol. 2024;49(4):102404.","journal-title":"Curr Probl Cardiol"},{"issue":"3","key":"4340_CR40","first-page":"e22770","volume":"14","author":"A Mohammadi","year":"2022","unstructured":"Mohammadi A, Balan I, Yadav S, Matos WF, Kharawala A, Gaddam M, et al. Post-COVID-19 Pulmonary Fibrosis. Cureus. 2022;14(3):e22770.","journal-title":"Cureus"},{"key":"4340_CR41","doi-asserted-by":"crossref","unstructured":"Hama Amin BJ, Kakamad FH, Ahmed GS, Ahmed SF, Abdulla BA, Mohammed SH et al. Post COVID-19 pulmonary fibrosis; a meta-analysis study. Annals of medicine and surgery (2012). 2022;77:103590.","DOI":"10.1016\/j.amsu.2022.103590"},{"issue":"4","key":"4340_CR42","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/atm.atm_7_23","volume":"18","author":"NN Alrajhi","year":"2023","unstructured":"Alrajhi NN. Post-COVID-19 pulmonary fibrosis: An ongoing concern. Ann Thorac Med. 2023;18(4):173\u201381.","journal-title":"Ann Thorac Med"},{"issue":"3","key":"4340_CR43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s41030-023-00226-y","volume":"9","author":"S Duong-Quy","year":"2023","unstructured":"Duong-Quy S, Vo-Pham-Minh T, Tran-Xuan Q, Huynh-Anh T, Vo-Van T, Vu-Tran-Thien Q, et al. Post-COVID-19 Pulmonary Fibrosis: Facts-Challenges and Futures: A Narrative Review. Pulmonary therapy. 2023;9(3):295\u2013307.","journal-title":"Pulmonary therapy"},{"key":"4340_CR44","doi-asserted-by":"crossref","unstructured":"Patrucco F, Solidoro P, Gavelli F, Apostolo D, Bellan M. Idiopathic Pulmonary Fibrosis and Post-COVID-19 Lung Fibrosis: Links and Risks. Microorganisms. 2023;11(4):895.","DOI":"10.3390\/microorganisms11040895"},{"issue":"4","key":"4340_CR45","doi-asserted-by":"publisher","first-page":"L520","DOI":"10.1152\/ajplung.00166.2024","volume":"327","author":"AJ Brownstein","year":"2024","unstructured":"Brownstein AJ, Mura M, Ruffenach G, Channick RN, Saggar R, Kim A, et al. Dissecting the lung transcriptome of pulmonary fibrosis-associated pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2024;327(4):L520\u201334.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"7","key":"4340_CR46","doi-asserted-by":"publisher","first-page":"e01179","DOI":"10.1002\/rcr2.1179","volume":"11","author":"H Nakayama","year":"2023","unstructured":"Nakayama H, Ishida M, Nakaoka H, Nishimura Y, Imai RI, Sugane H, et al. Pulmonary hypertension secondary to interstitial fibrosis with pulmonary venous lesions masquerading pulmonary veno-occlusive disease. Respirol case Rep. 2023;11(7):e01179.","journal-title":"Respirol case Rep"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04340-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04340-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04340-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:34:50Z","timestamp":1787870090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04340-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4340"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04340-w","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Medical Ethics Review Committee of the First Affiliated Hospital of Guangxi Medical University (2025-K0216). This study is based on data derived from original clinical trials that have obtained approval from relevant ethics review committees, strictly adhere to the principles of the Declaration of Helsinki and international standards for Good Clinical Practice (GCP), and have completed participant informed consent processes. The INFORMA database solely aggregates and processes anonymized trial project information that has undergone compliant de-identification procedures. It does not involve direct contact with patients or the collection of new personal data. Consequently, this study itself does not involve new human subjects, and its use of data is in compliance with ethical requirements for information obtained from legally and ethically compliant sources.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"378"}}